Related references
Note: Only part of the references are listed.Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin
Rebecca Danhof et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N. Basset-Seguin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib
Tina Bhutani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project
Beatrice J. Edwards et al.
DRUGS IN R&D (2017)
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
Ghassan K. Abou-Alfa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy
Zoe Apalla et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2017)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic et al.
BMC CANCER (2017)
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Christina Danial et al.
CLINICAL CANCER RESEARCH (2016)
A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
Vikram Malhi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Hedgehog signaling: modulation of cancer properties and tumor microenvironment (vol 15, 24, 2016)
Ann Hanna et al.
MOLECULAR CANCER (2016)
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Mario E. Lacouture et al.
ONCOLOGIST (2016)
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials
Anne Lynn S. Chang et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma
Celeste B. Burness et al.
TARGETED ONCOLOGY (2016)
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
Scott X. Atwood et al.
CANCER CELL (2015)
Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma
Hayley J. Sharpe et al.
CANCER CELL (2015)
Management of high-risk and advanced basal cell carcinoma
S. Puig et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Real-world treatment of vismodegib (VISMO)-related adverse events (AEs) in patients with locally advanced basal cell carcinoma: Report from the RegiSONIC Disease Registry Study
M. Lacouture et al.
EUROPEAN JOURNAL OF CANCER (2015)
The RegiSONIC Disease Registry Study: Safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma
M. Lacouture et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
Aleksandar Sekulic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Nicole Basset-Seguin et al.
LANCET ONCOLOGY (2015)
Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib
C. Saintes et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma
Sabrina Pricl et al.
MOLECULAR ONCOLOGY (2015)
Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib
T. Lu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Roles for Hedgehog signaling in adult organ homeostasis and repair
Ralitsa Petrova et al.
DEVELOPMENT (2014)
Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease
Margaret McCusker et al.
EUROPEAN JOURNAL OF CANCER (2014)
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib
Anne Lynn S. Chang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Drug resistance to targeted therapies: Deja vu all over again
Floris H. Groenendijk et al.
MOLECULAR ONCOLOGY (2014)
Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
Brigitte Dreno et al.
ONCOLOGIST (2014)
Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations
Shalini V. Mohan et al.
CURRENT DERMATOLOGY REPORTS (2014)
Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients
Manish R. Sharma et al.
CLINICAL CANCER RESEARCH (2013)
Systemic Therapy for Inoperable and Metastatic Basal Cell Cancer
Leslie A. Fecher
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis
Sophie C. Flohil et al.
EUROPEAN JOURNAL OF CANCER (2013)
The mechanisms of Hedgehog signalling and its roles in development and disease
James Briscoe et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
C. Lance Cowey
DERMATOLOGY AND THERAPY (2013)
Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
Anne Lynn S. Chang et al.
ARCHIVES OF DERMATOLOGY (2012)
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
Richard A. Graham et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Vismodegib In Locally Advanced or Metastatic Basal Cell Carcinoma
Gillian M. Keating
DRUGS (2012)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
Richard A. Graham et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry
Richard A. Graham et al.
DRUG METABOLISM AND DISPOSITION (2011)
GDC-0449-A potent inhibitor of the hedgehog pathway
Kirk D. Robarge et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma.
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
Lorenzo Lo Muzio
ORPHANET JOURNAL OF RARE DISEASES (2008)
Basal cell carcinomas: attack of the hedgehog
Ervin H. Epstein
NATURE REVIEWS CANCER (2008)
Share Paper
